Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Toxicol Ind Health ; 36(9): 619-633, 2020 Sep.
Article in English | MEDLINE | ID: covidwho-947902

ABSTRACT

Antimicrobial agents have become an essential tool in controlling the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and guidelines on their use have been issued by various public health agencies. Through its Emerging Viral Pathogen Guidance for Antimicrobial Pesticides, the US Environmental Protection Agency has approved numerous surface disinfectant products for use against SARS-CoV-2. Despite their widespread use and range of associated health hazards, the majority of active ingredients in antimicrobial products, such as surface disinfectants, lack established occupational exposure limits (OELs) to assist occupational health professionals in characterizing risks from exposures to these chemicals. Based on established approaches from various organizations, a framework for deriving OELs specific to antimicrobial agents was developed that relies on a weight-of-evidence evaluation of the available data. This framework involves (1) a screening-level toxicological assessment based on a review of the existing literature and recommendations, (2) identification of the critical adverse effect(s) and dose-response relationship(s), (3) identification of alternative health-based exposure limits (HBELs), (4) derivation of potential OELs based on identified points of departure and uncertainty factors and/or modification of existing alternative HBELs, and (5) selection of an appropriate OEL. To demonstrate the use of this framework, a case study is described for selection of an OEL for a disinfectant product containing quaternary ammonium compounds (quats). Three potential OELs were derived for this product based on irritation toxicity data, developmental and reproductive toxicity (DART) data, and modification of an existing HBEL. The final selected OEL for the quats-containing product was 0.1 mg/m3, derived from modification of an existing HBEL. This value represented the lowest resulting value of the three approaches, and thus, was considered protective of irritation and potential DART.


Subject(s)
Anti-Infective Agents/standards , Disinfectants/standards , Occupational Exposure/standards , Quaternary Ammonium Compounds/standards , Anti-Infective Agents/therapeutic use , COVID-19/prevention & control , Disinfectants/therapeutic use , Humans , Occupational Exposure/prevention & control , Occupational Health , Organizational Case Studies , Pandemics , Quaternary Ammonium Compounds/therapeutic use , Risk Assessment , SARS-CoV-2
2.
Eur Rev Med Pharmacol Sci ; 24(21): 11432-11439, 2020 Nov.
Article in English | MEDLINE | ID: covidwho-934955

ABSTRACT

OBJECTIVE: Soap has been used by humankind since ancient times and was probably already known to the Sumerians. It is a fatty acid salt obtained from the reaction of a strong base with a fatty substance of animal (tallow) or plant origin (oil). This reaction is called saponification. Syndets, on the other hand, are much more recent and have been in use for about a century. In the case of liquid syndets, they are mainly alkyl sulphates and their derivatives alkyl ether sulphates while isethionates and sarcosinates are more commonly found in solid syndets. Synthetic soaps and detergents are surfactants and, as such, they have detergent properties. The way soap works accounts for its antimicrobial properties. Thanks to its amphiphilic structure, it is able to interact with the lipid membranes of microorganisms (viruses, bacteria, etc.) and inactivate them. In this coronavirus pandemic period, health authorities worldwide recommend hand washing with soap and water. We therefore wanted to provide a summary of the chemical characteristics and applications of soaps, on the one hand, and synthetic detergents, on the other. Soap is not the only product used for hand hygiene and, given the current situation, alternatives are complex and varied.


Subject(s)
Anti-Infective Agents/pharmacology , Betacoronavirus/drug effects , Coronavirus Infections/prevention & control , Detergents/pharmacology , Hand Disinfection/methods , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Soaps/pharmacology , Anti-Infective Agents/chemistry , Anti-Infective Agents/standards , COVID-19 , Communicable Disease Control/methods , Communicable Disease Control/standards , Coronavirus Infections/epidemiology , Coronavirus Infections/transmission , Coronavirus Infections/virology , Detergents/chemistry , Detergents/standards , Hand Disinfection/standards , Humans , Pneumonia, Viral/epidemiology , Pneumonia, Viral/transmission , Pneumonia, Viral/virology , SARS-CoV-2 , Soaps/chemistry , Soaps/standards
5.
Cells ; 9(4)2020 04 08.
Article in English | MEDLINE | ID: covidwho-42137

ABSTRACT

The higher death rate caused by COVID-19 in older people, especially those with comorbidities, is a challenge for biomedical aging research. Here we explore the idea that an exacerbated inflammatory response, in particular that mediated by IL-6, may drive the deleterious consequences of the infection. Data shows that other RNA viruses, such as influenza virus, can display enhanced replication efficiency in senescent cells, suggesting that the accumulation of senescent cells with aging and age-related diseases may play a role in this phenomenon. However, at present, we are completely unaware of the response to SARS-CoV and SARS-COV-2 occurring in senescent cells. We deem that this is a priority area of research because it could lead to the development of several therapeutic strategies based on senotherapeutics or prevent unsuccessful attempts. Two of these senotherapeutics, azithromycin and ruxolitinib, are currently undergoing testing for their efficacy in treating COVID-19. The potential of these strategies is not only for ameliorating the consequences of the current emergence of SARS-CoV-2, but also for the future emergence of new viruses or mutated ones for which we are completely unprepared and for which no vaccines are available.


Subject(s)
Aging/immunology , Coronavirus Infections/drug therapy , Coronavirus Infections/immunology , Global Health/trends , Pneumonia, Viral/drug therapy , Pneumonia, Viral/immunology , Anti-Infective Agents/standards , Anti-Infective Agents/therapeutic use , Azithromycin/therapeutic use , COVID-19 , Cellular Senescence/immunology , Humans , Interleukin-6/immunology , Nitriles , Pandemics , Pyrazoles/therapeutic use , Pyrimidines
SELECTION OF CITATIONS
SEARCH DETAIL